Skip to main content

Spyre Therapeutics, Inc.

corporate_fare Company Profile

Spyre Therapeutics, Inc.

SYRE·NASDAQ·Life Sciences·CIK 0001636282

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations for inflammatory bowel disease ("IBD") and rheumatic diseases. The company's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23, which are being developed as both monotherapies and pair-wise combinations. Spyre's strategy involves three main pillars: advancing a portfolio of next-generation monotherapies, evaluating IBD combinations, and expanding its anti-TL1A program into additional indications. The next-generation monotherapy antibody candidates, SPY001, SPY002, and SPY003, target α4β7, TL1A, and IL-23, respectively. These candidates are engineered for optimized potency, selectivity, and pharmacokinetics ("PK") against validated IBD targets. They incorporate Fc domain modifications called YTE substitutions to increase pharmacokinetic half-life and are formulated as high-concentration, citrate-free formulations. These attributes aim to enable quarterly or twice annual subcutaneous ("SC") maintenance dosing. The company is also exploring fixed-dose-combinations of its investigational antibodies. The anti-TL1A program is being expanded into additional indications, starting with rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA").

Spyre Therapeutics, Inc. (NASDAQ:SYRE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for SYRE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for SYRE spans 10-Q, 8-K, 424B5, S-3ASR.

Recent high-impact activity:

  • Spyre Posts $96.1M Q3 Loss, $1.1B Cash, Runway Into 2H 2029
  • Spyre Posts $96.1M Q3 Loss, Expands HS Program With $1.5B Pro Forma Cash
  • Spyre Therapeutics 8-K Confirms $350M Offering at $85/Share
  • Spyre Prices $350M Public Offering at $85/Share, Adding $328.7M Net Proceeds
  • Spyre Therapeutics Stock Slides 12% After $350M Offering Priced at $85

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$155.2M
Op. Cash Flow
-$169.25M
Operating Income
-$209.56M
Cash & Equivalents
$85.72M
Debt / Equity
0.00×
Shares Outstanding
78.19M sh
Source: 10-K · filed 2026-02-19 · accession 0001636282-26-000020

Short Interest & Short Volume

12.69 days to cover

FINRA reported short interest of 11,617,573 shares in SYRE as of the October 30, 2026 settlement, a 7.1% decrease from the prior period — about 12.7 days to cover at its recent average daily volume. On November 20, 2026, 53.8% of SYRE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)11,617,573 shares as of October 30, 2026
Change vs prior period▼ 7.1%
Days to cover12.69 at avg daily volume of 915,434
Daily short volume (FINRA facilities)53.8% of 250,732 shares on November 20, 2026
5-day average short volume59.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for SYRE, detected from its recent SEC filings · based on capital-structure filings through 2026-10-06.

1 recent capital raiseATM program1 shelf registration

Public Offering Priced at $85/Share · Net Proceeds of $328.7M

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with S →
$93.47
52-week range · as of 2026-11-03 $21.14 – $110.17
Market cap
$8.88B
Volume
805.4K (0.8× avg)
3-mo avg 1M
Live data · 2026-11-22 05:22 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SYRE - Latest Insights

SYRE
Nov 03, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $99.73
Real-time Price: $93.47 info
Change: -$6.26 (-6%) info
Market Cap: $8.877B info
SYRE
Nov 03, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $99.73
Real-time Price: $93.47 info
Change: -$6.26 (-6%) info
Market Cap: $8.877B info
SYRE
Oct 07, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $80.51
Real-time Price: $93.47 info
Change: +$12.96 (+16%) info
Market Cap: $8.877B info
SYRE
Oct 06, 2026, 4:41 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $80.11
Real-time Price: $93.47 info
Change: +$13.36 (+17%) info
Market Cap: $8.877B info
SYRE
Oct 06, 2026, 11:53 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $81.16
Real-time Price: $93.47 info
Change: +$12.31 (+15%) info
Market Cap: $8.877B info
SYRE
Oct 05, 2026, 4:03 PM EDT
Source: Reuters
Importance Score:
7
Updated Oct 5, 8:15 PM ET — Spyre priced the offering at $85 per share for 4,117,648 shares, raising $350.0 million.
Price at Filing: $89.81
Real-time Price: $93.47 info
Change: +$3.66 (+4%) info
Market Cap: $8.877B info
SYRE
Sep 08, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $88.40
Real-time Price: $93.47 info
Change: +$5.07 (+6%) info
Market Cap: $8.877B info
SYRE
Sep 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $88.40
Real-time Price: $93.47 info
Change: +$5.07 (+6%) info
Market Cap: $8.877B info
SYRE
Aug 26, 2026, 10:46 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $96.50
Real-time Price: $93.47 info
Change: -$3.03 (-3%) info
Market Cap: $8.877B info
SYRE
Aug 25, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $94.77
Real-time Price: $93.47 info
Change: -$1.30 (-1%) info
Market Cap: $8.877B info
SYRE
Aug 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $104.94
Real-time Price: $93.47 info
Change: -$11.47 (-11%) info
Market Cap: $8.877B info
SYRE
Aug 04, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $104.94
Real-time Price: $93.47 info
Change: -$11.47 (-11%) info
Market Cap: $8.877B info
SYRE
Jun 26, 2026, 6:34 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $87.89
Real-time Price: $93.47 info
Change: +$5.58 (+6%) info
Market Cap: $8.877B info
SYRE
Jun 26, 2026, 4:05 PM EDT
Filing Type: S-3ASR
Importance Score:
8
Price at Filing: $87.80
Real-time Price: $93.47 info
Change: +$5.67 (+6%) info
Market Cap: $8.877B info
SYRE
Jun 23, 2026, 9:57 PM EDT
Filing Type: 144
Importance Score:
9
Price at Filing: $86.50
Real-time Price: $93.47 info
Change: +$6.97 (+8%) info
Market Cap: $8.877B info
SYRE
Jun 23, 2026, 9:56 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $86.50
Real-time Price: $93.47 info
Change: +$6.97 (+8%) info
Market Cap: $8.877B info
SYRE
Jun 23, 2026, 9:45 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $86.50
Real-time Price: $93.47 info
Change: +$6.97 (+8%) info
Market Cap: $8.877B info
SYRE
Jun 15, 2026, 8:03 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $82.50
Real-time Price: $93.47 info
Change: +$10.97 (+13%) info
Market Cap: $8.877B info
SYRE
Jun 15, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $82.50
Real-time Price: $93.47 info
Change: +$10.97 (+13%) info
Market Cap: $8.877B info
SYRE
Jun 03, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $69.67
Real-time Price: $93.47 info
Change: +$23.80 (+34%) info
Market Cap: $8.877B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets